Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

The mechanisms of action of PPARs

Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659

Roles of PPARs in health and disease

Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730

Adipogenesis and Obesity: Rounding Out the Big Picture

Spiegelman, B. M., & Flier, J. S. (1996) · Cell · doi:10.1016/s0092-8674(00)81359-8 · Cited by 1,262

Terminal Differentiation of Human Breast Cancer through PPARγ

Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., & Spiegelman, B. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80047-7 · Cited by 850

Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

Elstner, E., Müller‐Tidow, C., Koshizuka, K., Williamson, E. A., Park, D. J., Asou, H., Shintaku, P. I., SAID, J. W., Heber, D., & Koeffler, H. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8806 · Cited by 804

The Structure−Activity Relationship between Peroxisome Proliferator-Activated Receptor γ Agonism and the Antihyperglycemic Activity of Thiazolidinediones

Willson, T. M., Cobb, J. E., Cowan, D. J., Wiethe, R. W., Correa, I. D., Prakash, S. R., Beck, K. D., Moore, L. B., Kliewer, S. A., & Lehmann, J. M. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950395a · Cited by 637

Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., SAID, J. W., Holden, S. A., Miyoshi, I., & Koeffler, H. P. (1998) · PubMed · Cited by 589

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma

Demetri, G. D., Fletcher, C. D. �., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., & Singer, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3951 · Cited by 495

Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer

Mueller, E., Smith, M. R., Sarraf, P., Kroll, T. G., Aiyer, A., Kaufman, D. S., Oh, W. K., Demetri, G. D., Figg, W. D., Zhou, X.-P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180329197 · Cited by 427

Optimization of troglitazone derivatives as potent anti-proliferative agents: Towards more active and less toxic compounds

Bordessa, A., Colin, C., Grillier‐Vuissoz, I., Kuntz, S., Mazerbourg, S., Husson, G., Vo, M., Flament, S., Martin, H., Chapleur, Y., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.015 · Cited by 33

Troglitazone reverses the multiple drug resistance phenotype in cancer cells

Harkness (2009) · Drug Design Development and Therapy · doi:10.2147/dddt.s3314 · Cited by 31

Rosiglitazone Attenuates Insulin-Like Growth Factor 1 Receptor Survival Signaling in PC-3 Cells

Papageorgiou, E. G., Pitulis, N., Manoussakis, M. N., Lembessis, P., & Koutsilieris, M. (2008) · Molecular Medicine · doi:10.2119/2008-00021.papageorgiou · Cited by 32

Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance

Skildum, A. J., Dornfeld, K. J., & Wallace, K. B. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1268-2 · Cited by 32

New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines

Colin, C., Salamone, S., Grillier‐Vuissoz, I., Boisbrun, M., Kuntz, S., Lecomte, J., Chapleur, Y., & Flament, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0700-y · Cited by 31

Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells

Cellai, I., Benvenuti, S., Luciani, P., Galli, A., Ceni, E., Simi, L., Baglioni, S., Muratori, M., Ottanelli, B., Serio, M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603344 · Cited by 31

Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells

Terrasi, M., Bazan, V., Caruso, S., Insalaco, L., Amodeo, V., Fanale, D., Corsini, L. R., Contaldo, C., Mercanti, A., Fiorio, E., et al. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24295 · Cited by 31

Induction of G 1 phase arrest and apoptosis in MDA‐MB‐231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator‐activated receptor γ (PPARγ) ligand

Yu, H., Lee, Y., Noh, E., Lee, K., Kim, J., Song, E., Han, M., Lee, Y., Kwon, K., Lee, S., et al. (2008) · Cell Biology International · doi:10.1016/j.cellbi.2008.04.011 · Cited by 30

COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situ

Kulkarni, S., Patil, D. B., Diaz, L. K., Wiley, E. L., Morrow, M., & Khan, S. A. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-36 · Cited by 30

Activation of Peroxisome Proliferator-Activated Receptor γ Contributes to the Survival of T Lymphoma Cells by Affecting Cellular Metabolism

Yang, C., Jo, S., Csernus, B., Hyjek, E. M., Liu, Y., Chadburn, A., & Wang, Y. L. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060651 · Cited by 29

Fluorine-18 labeling and biodistribution studies on peroxisome proliferator-activated receptor-γ ligands: potential positron emission tomography imaging agents

Lee, B. C., Dence, C. S., Zhou, H., Parent, E. E., Welch, M. J., & Katzenellenbogen, J. A. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.11.002 · Cited by 29

The PPARγ agonist pioglitazone prevents the hyperglycemia caused by phosphoinositide-3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Ihle, N., Lemos, R., Schwartz, D., Oh, J., Halter, R., Wipf, P., Kirkpatrick, L., & Powis, G. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0714 · Cited by 30

PPARγ‐inactive Δ2‐troglitazone independently triggers ER stress and apoptosis in breast cancer cells

Colin, C., Yao, X., Cerella, C., Chbicheb, S., Kuntz, S., Mazerbourg, S., Boisbrun, M., Chapleur, Y., Diederich, M. F., Flament, S., et al. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22109 · Cited by 28

Human Breast Cancer Xenograft Model Implicates Peroxisome Proliferator–activated Receptor Signaling as Driver of Cancer-induced Muscle Fatigue

Wilson, H. E., Rhodes, K. K., Rodríguez, D., Chahal, I. K., Stanton, D. A., Bohlen, J. F., Davis, M. C., Infante, A. M., Hazard-Jenkins, H. W., Klinke, D. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1565 · Cited by 28

Dual PPARγ/ɑ agonist oroxyloside suppresses cell cycle progression by glycolipid metabolism switch-mediated increase of reactive oxygen species levels

Zhou, Y., Guo, Y., Zhu, Y., Sun, Y., Li, W., Li, Z., & Wei, L. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.032 · Cited by 28

Transactivation of ERα by Rosiglitazone induces proliferation in breast cancer cells

Talbert, D. R., Allred, C. D., Zaytseva, Y. Y., & Kilgore, M. W. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9575-y · Cited by 28

PPARs: Interference with Warburg’ Effect and Clinical Anticancer Trials

Vamecq, J., Colet, J., Eynde, J. J. V., Briand, G., Porchet, N., & Rocchi, S. (2012) · PPAR Research · doi:10.1155/2012/304760 · Cited by 28

Advances in Combination of Antiangiogenic Agents Targeting VEGF-binding and Conventional Chemotherapy and Radiation for Cancer Treatment

Teng, L., Jin, K., He, K., Wang, H., Cao, J., & Yu, D.-C. (2010) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(10)70062-9 · Cited by 28

Antihyperglycaemic therapies and cancer risk

Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 28

In vivo effects of rosiglitazone in a human neuroblastoma xenograft

Cellai, I., Petrangolini, G., Tortoreto, M., Pratesi, G., Luciani, P., Deledda, C., Benvenuti, S., Ricordati, C., Gelmini, S., Ceni, E., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605506 · Cited by 26

Troglitazone inhibits the migration and invasion of PC‑3 human prostate cancer cells by upregulating E‑cadherin and glutathione peroxidase 3

Chang, S., Lee, J. Y., Oh, H., Kim, U., Ryu, B., & Park, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9278 · Cited by 26

Strategies for the Labeling of Halogen-Substituted Peroxisome Proliferator-Activated Receptor γ Ligands: Potential Positron Emission Tomography and Single Photon Emission Computed Tomography Imaging Agents

Lee, B. C., Lee, K. C., Lee, H. S., Mach, R. H., & Katzenellenbogen, J. A. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060191g · Cited by 26

Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells

Yu, H., Noh, E.-M., Lee, Y.-R., Roh, S., Song, E.-K., Han, M., Lee, Y.-C., Shim, I. K., Lee, S. J., Jung, S. H., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.111 · Cited by 26

PPAR Ligands for Cancer Chemoprevention

Yasui, Y., Kim, M.-H., & Tanaka, T. (2008) · PPAR Research · doi:10.1155/2008/548919 · Cited by 25

In Vivo RNAi Screen Unveils PPARγ as a Regulator of Hematopoietic Stem Cell Homeostasis

Sertorio, M. G., Du, W., Amarachintha, S. P., Wilson, A., & Pang, Q. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.03.008 · Cited by 25

Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis

Heudobler, D., Rechenmacher, M., Lüke, F., Vogelhuber, M., Klobuch, S., Thomas, S., Pukrop, T., Hackl, C., Herr, W., Ghibelli, L., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01357 · Cited by 24

Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas

Horvai, A., Schaefer, J. T., Nakakura, E. K., & O’Donnell, R. J. (2008) · Modern Pathology · doi:10.1038/modpathol.3801017 · Cited by 24

The Key to Unlocking the Chemotherapeutic Potential of PPARγLigands: Having the Right Combination

Skelhorne‐Gross, G., & Nicol, C. J. B. (2012) · PPAR Research · doi:10.1155/2012/946943 · Cited by 23

Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells

Rashid-Kolvear, F., Taboski, M. A. S., Nguyen, J., Wang, D., Harrington, L. A., & Done, S. J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-390 · Cited by 23

Troglitazone inhibits histone deacetylase activity in breast cancer cells

Davies, G. F., Ross, A. R. S., Arnason, T., Juurlink, B. H. J., & Harkness, T. A. A. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.07.011 · Cited by 23

A Phase I Study of Bexarotene and Rosiglitazone in Patients with Refractory Cancers

Read, W. L., Baggstrom, M. Q., Fracasso, P. M., & Govindan, R. (2008) · Chemotherapy · doi:10.1159/000140468 · Cited by 23

HL005—A new selective PPARγ antagonist specifically inhibits the proliferation of MCF-7

Lü, W., Che, P., Zhang, Y., Li, H., Zou, S., Zhu, J., Deng, J., Shen, X., Jiang, H., Li, J., et al. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.01.019 · Cited by 23

In vitro and in vivo therapeutic efficacy of the PPAR‐γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth

Hamaguchi, N., Hamada, H., Miyoshi, S., Irifune, K., Ito, R., Miyazaki, T., & Higaki, J. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01632.x · Cited by 23

Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas

Frapolli, R., Bello, E., Ponzo, M., Craparotta, I., Mannarino, L., Ballabio, S., Marchini, S., Carrassa, L., Ubezio, P., Porcu, L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0976 · Cited by 22

Retinoid X receptor alpha (RXRα) and peroxisome proliferator-activated receptor gamma (PPARγ) expression in breast cancer: an immunohistochemical study.

Ditsch, N. C., Vrekoussis, T., Lenhard, M. S., Rühl, I., Gallwas, J. K. S., Weissenbacher, T., Friese, K., Mayr, D. C., Makrigiannakis, A., & Jeschke, U. (2012) · PubMed · Cited by 22

Anti-leukemic effects of PPARγ ligands

Ryu, S., Kim, D. S., Lee, M. W., Lee, J. W., Sung, K. W., Koo, H. H., & Yoo, K. H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.020 · Cited by 21

VSP‑17 suppresses the migration and invasion of triple‑negative breast cancer cells through inhibition of the EMT process via the PPARγ/AMPK signaling pathway

Xu, X., Liu, M., Yang, Y., Wei, C., Zhang, X., Song, H., Wang, Y., & Duan, X. (2020) · Oncology Reports · doi:10.3892/or.2020.7916 · Cited by 21

Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers

Loo, S. Y., Syn, N. L. X., Koh, A. P.-F., Teng, J. C.-F., Deivasigamani, A., Tan, T. Z., Thike, A. A., Vali, S., Kapoor, S., Wang, X., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00635-5 · Cited by 22

Type 2 Diabetes Mellitus, Oral Diabetic Medications, Insulin Therapy, and Overall Breast Cancer Risk

Ahmadieh, H., & Azar, S. T. (2013) · ISRN Endocrinology · doi:10.1155/2013/181240 · Cited by 21

Peroxisome proliferator-activated receptor α expression is regulated by estrogen receptor α and modulates the response of MCF-7 cells to sodium butyrate

Faddy, H. M., Robinson, J. A., Lee, W. J., Holman, N. A., Monteith, G. R., & Roberts‐Thomson, S. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.09.002 · Cited by 21

Role of Epidermal Growth Factor Receptor (EGFR)-Signaling Versus Cellular Acidosis Via Na+/H+ Exchanger1(NHE1)-Inhibition in Troglitazone-Induced Growth Arrest of Breast Cancer-Derived Cells MCF-7

Friday, E., Oliver, R., Welbourne, T., & Turturro, F. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110435 · Cited by 21

The Anticancer Potential of Peroxisome Proliferator‐Activated Receptor Antagonists

Lellis, L. D., Cimini, A., Veschi, S., Benedetti, E., Amoroso, R., Cama, A., & Ammazzalorso, A. (2017) · ChemMedChem · doi:10.1002/cmdc.201700703 · Cited by 20

Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate

Yadav, S., Pandey, S. K., Goel, Y., Temre, M. K., & Singh, S. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00728 · Cited by 19

Melatonin May Increase Anticancer Potential of Pleiotropic Drugs

Bojková, B., Kubatka, P., Qaradakhi, T., Zulli, A., & Kajo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123910 · Cited by 21

Simvastatin-romidepsin combination kills bladder cancer cells synergistically

Okubo, K., Miyai, K., Kato, K., Asano, T., & Sato, A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101154 · Cited by 19

Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin

Bontempo, A., Ugalde-Villanueva, B., Delgado-González, E., Rodríguez, Á. L., & Aceves, C. (2017) · Oncology Reports · doi:10.3892/or.2017.5934 · Cited by 18

Metabolic syndrome and breast cancer: an overview.

Gezgen, G., Roach, E. C., Kızılarslanoğlu, M. C., Petekkaya, İ., & Altundağ, K. (2012) · PubMed · Cited by 18

Synthesis and evaluation of a bromine-76-labeled PPARγ antagonist 2-bromo-5-nitro-N-phenylbenzamide

Lee, H. S., Finck, B. N., Jones, L. A., Welch, M. J., & Mach, R. H. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.08.003 · Cited by 18

Anticancer Role of PPAR γ Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes

Simpson‐Haidaris, P. J., Pollock, S. J., Ramon, S., Guo, N., Woeller, C. F., Feldon, S. E., & Phipps, R. P. (2010) · PPAR Research · doi:10.1155/2010/814609 · Cited by 18

PPARgamma: A Potential Intrinsic and Extrinsic Molecular Target for Breast Cancer Therapy

Augimeri, G., & Bonofiglio, D. (2021) · Biomedicines · doi:10.3390/biomedicines9050543 · Cited by 17

Therapeutic Implications of Targeting Energy Metabolism in Breast Cancer

Sakharkar, M. K., Shashni, B., Sharma, K., Dhillon, S. K., Ranjekar, P. R., & Sakharkar, K. R. (2013) · PPAR Research · doi:10.1155/2013/109285 · Cited by 17

PPARγ-independent Activity of Thiazolidinediones: A Promising Mechanism of Action for New Anticancer Drugs?

Grillier‐Vuissoz, I., & Mazerbourg, S. (2012) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s8-002 · Cited by 18

Synergistic Interactions between Heregulin and Peroxisome Proliferator-activated Receptor-γ (PPARγ) Agonist in Breast Cancer Cells

Park, B.-H., Lee, S.-B., Stolz, D. B., Lee, Y. J., & Lee, B.-C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.191718 · Cited by 16

PPARγ Agonists Target Aromatase Via Both PGE2 and BRCA1

Margalit, O., Wang, D., & DuBois, R. N. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0365 · Cited by 16

Expression of peroxisome proliferator activated receptor γ and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma

Stadlmann, S., Gueth, U., Wight, E., Kunz‐Schughart, L. A., Hartmann, A., & Singer, G. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.035717 · Cited by 16

Thiazolidinedione anti-cancer activity: Is inhibition of microtubule assembly implicated?

Russu, W. A. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.06.054 · Cited by 16

CRITICAL REVIEW IN PHARMACEUTICAL SCIENCES

publisher, P. E. (2014) · ADVANCED SCIENCES INDEX · Cited by 16

Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging

Morosi, L., Matteo, C., Meroni, M., Ceruti, T., Nerini, I. F., Bello, E., Frapolli, R., D’Incalci, M., Zucchetti, M., & Davoli, E. (2021) · Talanta · doi:10.1016/j.talanta.2021.122918 · Cited by 15

Bisphenol A is a carcinogen that induces lipid accumulation, peroxisome proliferator‑activated receptor‑γ expression and liver disease

Ismael, L. Q., Abdulhameed, A.-S. A. R., Keong, Y., Abdullah, M. N., Bahari, H., Jie, T., & Yin, K. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11671 · Cited by 15

Loss of PPARγ activity characterizes early protumorigenic stromal reprogramming and dictates the therapeutic window of opportunity

Caruso, J. A., Wang, X., Murrow, L. M., Rodríguez, C. I., Chen‐Tanyolac, C., Vu, L., Chen, Y., Gascard, P. D., Gartner, Z. J., Kerlikowske, K. M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303774120 · Cited by 17

Differentiation Therapy

Chen, S., Yan, X., Zhou, G., & Chen, Z. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm011 · Cited by 15

Thiazolidinedione derivatives in cancer therapy: exploring novel mechanisms, therapeutic potentials, and future horizons in oncology

Ranjan, G., Ranjan, S., Sunita, P., & Pattanayak, S. P. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03661-z · Cited by 14

Anticancer Activities of PPARγ in Breast Cancer Are Context-Dependent

Dong, J. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.03.005 · Cited by 14

Thiazolidinediones abrogate cervical cancer growth

Wuertz, B. R. K., Darrah, L., Wudel, J., & Ondrey, F. G. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.02.020 · Cited by 14

VSP-17, a New PPARγ Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer via Upregulating the Expression of E-Cadherin

Wang, Y., Zhu, M., Yuan, B., Zhang, K., Zhong, M., Yi, W., Xu, X., & Duan, X. (2018) · Molecules · doi:10.3390/molecules23010121 · Cited by 14

Pioglitazone enhances cisplatin’s impact on triple-negative breast cancer: Role of PPARγ in cell apoptosis

Alqahtani, Q. H., Al‐Kharashi, L. A., Alajami, H. N., Alkharashi, I., Alkharashi, L., & Alhinti, S. N. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102059 · Cited by 13

Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol

Takeuchi, A., Nomura, A., Yamamoto, N., Hayashi, K., Igarashi, K., Tandai, S., Kawai, A., Matsumine, A., Miwa, S., Nishida, Y., et al. (2019) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-019-2453-z · Cited by 13

Differential effects of PPARγ activation by the oral antidiabetic agent pioglitazone in Barrett’s carcinoma in vitro and in vivo

Al‐Taie, O., Graf, T., Illert, B., Katzenberger, T., Mörk, H., Kraus, M. R., Barthelmes, H. U., Scheurlen, M., & Seufert, J. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0086-y · Cited by 13

To Live or to Die: Prosurvival Activity of PPARγ in Cancers

Wang, Y. L., & Miao, Q. (2008) · PPAR Research · doi:10.1155/2008/209629 · Cited by 14

Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: The REALIZE study

Takeuchi, A., Endo, M., Kawai, A., Nishida, Y., Terauchi, R., Matsumine, A., Aiba, H., Nakamura, T., Tandai, S., Ozaki, T., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.900010 · Cited by 12

Structurally diverse peroxisome proliferator‐activated receptor agonists induce apoptosis in human uro‐epithelial cells by a receptor‐independent mechanism involving store‐operated calcium channels

Chopra, B., Georgopoulos, N. T., Nicholl, A., Hinley, J., Oleksiewicz, M. B., & Southgate, J. (2009) · Cell Proliferation · doi:10.1111/j.1365-2184.2009.00628.x · Cited by 15

Improving the efficacy of trastuzumab in breast cancer

Suzuki, E., & Toi, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00455.x · Cited by 12

Positive and negative effects of glitazones in carcinogenesis: Experimental models vs. clinical practice

Bojková, B., Orendáš, P., Kubatka, P., Péč, M., Kassayová, M., Kisková, T., & Kajo, K. (2014) · Pathology - Research and Practice · doi:10.1016/j.prp.2014.06.003 · Cited by 11

Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer

Núñez‐Anita, R. E., Cajero-Juárez, M., & Aceves, C. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796798931 · Cited by 11

Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention

Rosas, R. R., Nachbor, K. M., Handley, N. R., Mathison, G., Wuertz, B. R. K., Ba’th, F., & Ondrey, F. G. (2021) · Head & Neck · doi:10.1002/hed.26959 · Cited by 11

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes

Baranova, A. V. (2008) · PPAR Research · doi:10.1155/2008/230893 · Cited by 11

PPARγ: The Portrait of a Target Ally to Cancer Chemopreventive Agents

Sainis, I., Vareli, K., Karavasilis, V., & Briasoulis, E. C. (2008) · PPAR Research · doi:10.1155/2008/436489 · Cited by 11

Thiazolidine-2,4-Dione

Chadha, N., & Silakari, O. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-102083-8.00005-4 · Cited by 10

Mistletoe lectin‐I augments antiproliferative effects of the PPARγ agonist rosiglitazone on human malignant melanoma cells

Freudlsperger, C., Dahl, A., Hoffmann, J., Reinert, S., & Schumacher, U. (2010) · Phytotherapy Research · doi:10.1002/ptr.3122 · Cited by 10

First Evidence for a Role of Siglec-8 in Breast Cancer

Trebo, A., Ditsch, N. C., Degenhardt, T., Kühn, C., Rahmeh, M., Schmoeckel, E., Mayr, D. C., Czogalla, B., Kolben, T., Meister, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042000 · Cited by 9

Effect of rosiglitazone on N-nitroso-N-methylurea-induced mammary tumors in rat.

Núñez, M., Martín, G., Cocca, C., Mohamad, N. A., Gutiérrez, A., Cricco, G., Medina, V. A., Rivera, E., Croci, M., Crescenti, E. J., et al. (2006) · PubMed · Cited by 9

Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands

Han, J. S., & Crowe, D. L. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-629 · Cited by 9

Investigation of the association between metabolic syndrome and breast cancer patients

Eskandari, D., Khodabandehloo, N., Gholami, A., Samadanifard, H., & Hejrati, A. (2020) · European Journal of Translational Myology · doi:10.4081/ejtm.2019.8776 · Cited by 9

Diabetes and Cancer: The Epidemiological and Metabolic Associations

Zhang, C., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_16 · Cited by 9

Ontology-based knowledge management of troglitazone-induced hepatotoxicity

Hug, H., Dannecker, R., Schindler, R., Bagatto, D., Stephan, A., Wess, R. A., & Gut, J. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03252-0 · Cited by 8

Modulating cell differentiation in cancer models

Fulghieri, P., Stivala, L. A., & Sottile, V. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210230 · Cited by 7

Retinoids Augment Thiazolidinedione PPARγ Activation in Oral Cancer Cells

Rosas, R., Buryska, S. M., SILVER, R., Wuertz, B. R. K., & Ondrey, F. G. (2020) · Anticancer Research · doi:10.21873/anticanres.14288 · Cited by 6

Complete necrosis of a giant cell tumor with high expression of PPARγ: a case report.

Takeuchi, A., Yamamoto, N., Nishida, H., Kimura, H. J., Ikeda, H., & Tsuchiya, H. (2013) · PubMed · Cited by 6

Synthesis and Binding Affinity of a Fluorine-Substituted Peroxisome Proliferator-Activated Gamma (PPARγ) Ligand as a Potential Positron Emission Tomography (PET) Imaging Agent

Lee, B. C., Lee, K. C., Lee, H. S., Mach, R. H., & Katzenellenbogen, J. A. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060190o · Cited by 6

Metabolic Effects of Pioglitazone in Chemically-Induced Mammary Carcinogenesis in Rats

Bojková, B., Garajová, M., Péč, M., Kubatka, P., Kajo, K., Mokáň, M., Kassayová, M., Orendáš, P., Kisková, T., Ahlersová, E., et al. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9399-2 · Cited by 5

Potential Benefits of Glitazones for Cancer and Vascular Disease

Pérez-Ortiz, J., Llorens, S., Llopis, J., Tranque, P., & Nava, E. (2008) · Current Drug Therapy · doi:10.2174/157488508784221271 · Cited by 4

Growth inhibiton of human breast cancer cell line MDA-MB-231 by rosiglitazone through activation of PPARγ

Zhang, T., Zhang, Q., Chen, D., Jiang, J., & Zhou, Q. (2008) · Chinese Journal of Clinical Oncology · doi:10.1007/s11805-008-0407-6 · Cited by 5

Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer‐bearing dogs

Frazier, S. A., McKemie, D. S., Guerrero, T. A., LaChapelle, H. M., Skorupski, K. A., Kass, P. H., & Rodriguez, C. O. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2012.00322.x · Cited by 6

PPARs and Anticancer Therapies

Robbins, M. E. C., Linard, C., & Panigrahy, D. (2010) · PPAR Research · doi:10.1155/2010/536415 · Cited by 5

From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies

Modica, R., Liccardi, A., Zamponi, V., Gagliardi, A., Nistor, A., Veroi, G., Arecco, A., Faggiano, A., & Colao, A. (2026) · Endocrine · doi:10.1007/s12020-026-04644-1 · Cited by 5

PPARγ antagonism as a new tool for preventing or overcoming endocrine resistance in luminal A breast cancers

Boretto, C., Muzio, G., & Autelli, R. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117461 · Cited by 4

Peroxisome proliferator-activated receptor subtypes in mammary gland development and breast cancer

Falconer, C., Kenny, P. A., Smart, C. E., Monteith, G. R., & Roberts‐Thomson, S. J. (2012) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-1-14 · Cited by 4

Peroxisome proliferator-activated receptor γ ligand troglitazone and TRAIL synergistically induce apoptosis

Koyama, M., Sowa, Y., Horinaka, M., Goda, A. E., Fujiwara, J., & Sakai, T. (2013) · Oncology Reports · doi:10.3892/or.2013.2868 · Cited by 4

Potential Mechanisms Linking Insulin to Cancer

Babichev, Y., Khalid, S., & Fantus, I. G. (2011) · Energy balance and cancer · doi:10.1007/978-1-4419-9911-5_7 · Cited by 4

Peroxisome proliferator‐activated receptor gamma, a possible culprit in mycosis fungoides: an immunohistochemical study

Youssef, R., Hegazy, R. A., Fawzy, M. M., Halim, D. M. A., Nabil, N., Sayed, S., & Shaker, O. G. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04333.x · Cited by 2

[Troglitazone sensitizes effect of epirubicin on breast cancer cells].

Sun, J., Meng, Z., Lv, J., & Sun, Y. (2006) · PubMed · Cited by 2

Peroxisome proliferator-activated receptor γ (PPARγ) ligand, troglitazone sensitizes breast cancer cells to tamoxifen-induced apoptosis

Kim, J., Lee, Y., Yu, H., Kim, B.-S., Youn, H. J., & Jung, S. H. (2007) · Molecular Cancer Therapeutics

Induction of cell cycle arrest and apoptosis in breast cancer cells by troglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligand.

Youn, H. J., Lee, B., Jung, S., Park, M., Yoon, J., Lee, J., & Choi, M. S. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-5034

Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-term Therapy on Tumor Tissue and Serum Markers

Yee, L. D., Williams, N., Wen, P., Young, D. C., Lester, J., Johnson, M. V., Farrar, W. B., Walker, M. J., Povoski, S. P., Suster, S. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1947 · Cited by 98

The effects of rosiglitazone therapy in early stage breast cancer

Yee, L. D., Williams, N., Wen, P., Young, D. C., Lester, J., Johnson, M. V., Farrar, W. B., Walker, M. J., Povoski, S. P., Suster, S. M., et al. (2006) · Cancer Research